NCT07315217Not yet recruiting
Cortical Excitability and Role of Non Invasive Brain Stimulation in ADHD and AUTISM
Cortical Excitability and Role of Non Invasive Brain Stimulation in ADHD and AUTISM : Double Blind Randomized Clinical Trial
Source: ClinicalTrials.gov · Last updated 2 Jan 2026
Brief summary (registry, in English)
This double-blind, randomized, sham-controlled clinical trial will evaluate the effects of repetitive transcranial magnetic stimulation (rTMS) on children and adolescents with attention-deficit/hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) and matched healthy controls. Participants aged 6-19 years will be assigned to active or sham rTMS protocols targeting the dorsolateral prefrontal cortex over 3 weeks, with assessment of changes in disorder-specific symptoms and cortical excitability. The study aims to determine the safety, feasibility, and preliminary efficacy of rTMS as a non-invasive neuromodulation approach in pediatric neurodevelopmental disorders.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 80 (estimated)
- First submitted
- 18 Dec 2025
- Start date
- Jan 2026
- Primary completion date
- Jan 2027
- Lead sponsor
- Assiut University
- Diseases
- Autism
- NCT number
- NCT07315217
What you commit to
- Study type: Interventional
- Planned participants: 80
- From Jan 2026 to the primary completion date, Jan 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Metallic implants or devices incompatible with TMS.
Other illness
- Epilepsy or seizure history.
- Severe psychiatric comorbidity (e.g., psychosis).
Other
- Inability to tolerate TMS procedures.
Who the study is looking for
- Age 6-19 years.
- ASD trial: DSM-5 diagnosis of ASD confirmed by CARS-2.
- ADHD trial: DSM-5 diagnosis of ADHD confirmed by structured interview/CONORS
- IQ ≥ 70.
- Stable medication for ≥4 weeks (if any).
Age in the registry: 6 years to 19 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.